{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:35:23Z","timestamp":1791812123895,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucose transporter 1 (GLUT1) is a key protein for transmembranous glucose uptake of cells which is often overexpressed in cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To better comprehend the prevalence and role of GLUT1 expression in different cancer types, a tissue microarray containing 14,966 samples from 134 different tumor entities was analyzed in this study. GLUT1 expression was generally markedly higher in cancer than in corresponding normal tissues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 122 of 134 tumor categories showed GLUT1 expression in at least 1 case, and 97 tumor categories included at least 1 case with strong GLUT1 staining. The frequency of GLUT1 positivity was particularly high in squamous cell carcinomas of various sites of origin (92.9%-100%), urothelial neoplasms (91.3%-98.7%), and carcinomas of the ovary and the endometrium (up to 100%). Elevated levels of GLUT1 staining were often associated with parameters of cancer aggressiveness. For example, high GLUT1 staining was associated with invasive growth of urothelial carcinomas (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0003), high grade (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0075), advanced pT stage (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.025), and shorter survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0031) in clear cell renal cell carcinoma, high grade (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0500) and distant metastasis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011), as well as shorter recurrence free survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0253) in papillary renal cell carcinoma, high grade in invasive breast cancer of no special type (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0003), advanced pT stage (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0008), nodal metastasis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0007), V1 status (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), and L1 status (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0008) in colorectal adenocarcinoma, and advanced pT stage (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0459) and MMR deficiency (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0018) in gastric cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>It is concluded, that GLUT1 is highly expressed in a broad range of tumor entities, that it occurs more often in malignant than in benign tumors, and that it is linked to aggressive behavior in many different entities. These findings identify GLUT1 as a critical prognostic cancer marker, which may be clinically useful in many cancer types.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15527-5","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T10:52:23Z","timestamp":1768042343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types"],"prefix":"10.1186","volume":"26","author":[{"given":"Seyma","family":"B\u00fcy\u00fccek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Viehweger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Schlichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Menz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M","family":"Luebke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Reiswich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Hube-Magg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hinsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Lennartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bernreuther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lebok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Fraune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Gorbokon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Burandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Minner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Steurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till S","family":"Clauditz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Krech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Chirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"issue":"3","key":"15527_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211\u20138.","journal-title":"Trends Biochem Sci"},{"issue":"2\u20133","key":"15527_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mam.2012.07.001","volume":"34","author":"M Mueckler","year":"2013","unstructured":"Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013;34(2\u20133):121\u201338.","journal-title":"Mol Aspects Med"},{"issue":"9","key":"15527_CR3","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00424-020-02448-4","volume":"472","author":"EM Wright","year":"2020","unstructured":"Wright EM. SGLT2 and cancer. Pflugers Arch. 2020;472(9):1407\u201314.","journal-title":"Pflugers Arch"},{"issue":"4","key":"15527_CR4","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3892\/ol.2015.3524","volume":"10","author":"K Iwasaki","year":"2015","unstructured":"Iwasaki K, Yabushita H, Ueno T, Wakatsuki A. Role of hypoxia-inducible factor-1alpha, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer. Oncol Lett. 2015;10(4):1970\u20138.","journal-title":"Oncol Lett"},{"key":"15527_CR5","doi-asserted-by":"crossref","unstructured":"Azcue P, Guerrero Setas D, Encio I, Ibanez-Beroiz B, Mercado M, Vera R, et al. A novel prognostic biomarker panel for early-stage colon carcinoma. Cancers (Basel). 2021;13(23):5909.","DOI":"10.3390\/cancers13235909"},{"key":"15527_CR6","doi-asserted-by":"crossref","unstructured":"Blayney JK, Cairns L, Li G, McCabe N, Stevenson L, Peters CJ, et al. Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma. Oncotarget. 2018;9(26):18518\u201328.","DOI":"10.18632\/oncotarget.24906"},{"key":"15527_CR7","doi-asserted-by":"crossref","unstructured":"Ito R, Yashiro M, Tsukioka T, Izumi N, Komatsu H, Inoue H, Yamamoto Y, et al. GLUT1 and PKM2 May be useful prognostic predictors in patients with non\u2013small cell lung cancer following curative R0 resection. Oncol Lett. 2023;25(3):129.","DOI":"10.3892\/ol.2023.13715"},{"issue":"9","key":"15527_CR8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1080\/00365520903121685","volume":"44","author":"M Legan","year":"2009","unstructured":"Legan M, Luzar B, Marolt VF. Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis. Scand J Gastroenterol. 2009;44(9):1101\u20138.","journal-title":"Scand J Gastroenterol"},{"key":"15527_CR9","doi-asserted-by":"crossref","unstructured":"Fujinaga A, Hirashita T, Hirashita Y, Sakai K, Kawamura M, Masuda T, et al. Glucose metabolic upregulation via phosphorylation of S6 ribosomal protein affects tumor progression in distal cholangiocarcinoma. BMC Gastroenterol. 2023;23(1):157.","DOI":"10.1186\/s12876-023-02815-2"},{"key":"15527_CR10","doi-asserted-by":"crossref","unstructured":"Wang L, Li M, Dong T, Li Y, Yin C, Nie F. Pancreatic ductal adenocarcinoma: the characteristics of contrast-enhanced ultrasound are correlated with the hypoxic microenvironment. Diagnostics (Basel). 2023;13(20):3270.","DOI":"10.3390\/diagnostics13203270"},{"key":"15527_CR11","doi-asserted-by":"crossref","unstructured":"Hur H, Xuan Y, Kim YB, Lee G, Shim W, Yun J, et al. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol. 2013;42(1):44\u201354.","DOI":"10.3892\/ijo.2012.1687"},{"key":"15527_CR12","doi-asserted-by":"crossref","unstructured":"Suteau V, Bukasa-Kakamba J, Virjogh-Cenciu B, Adenis A, Sabbah N, Drak Alsibai K. Pathological significance of GLUT-1 expression in breast cancer cells in diabetic and obese patients: the French Guiana study. Cancers (Basel). 2022;14(2):437.","DOI":"10.3390\/cancers14020437"},{"key":"15527_CR13","doi-asserted-by":"crossref","unstructured":"Pliszka M, Szablewski L. Glucose transporters as a target for anticancer therapy. Cancers (Basel). 2021;3(16):4184.","DOI":"10.3390\/cancers13164184"},{"key":"15527_CR14","doi-asserted-by":"crossref","unstructured":"Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844\u20137.","DOI":"10.1038\/nm0798-844"},{"key":"15527_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4939-3204-7_3","volume":"1381","author":"AM Dancau","year":"2016","unstructured":"Dancau AM, Simon R, Mirlacher M, Sauter G. Tissue microarrays. Methods Mol Biol. 2016;1381:53\u201365.","journal-title":"Methods Mol Biol"},{"key":"15527_CR16","doi-asserted-by":"crossref","unstructured":"Wu Q, Ba-Alawi W, Deblois G, Cruickshank J, Duan S, Lima-Fernandes E, et al. GLUT1 Inhibition blocks growth of RB1-positive triple negative breast cancer. Nat Commun. 2020;11(1):4205.","DOI":"10.1038\/s41467-020-18020-8"},{"key":"15527_CR17","doi-asserted-by":"crossref","unstructured":"Ren X, Cheng Z, He J, Yao X, Liu Y, Cai K, et al. Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint Blockade therapy in triple negative breast cancer. Nat Commun. 2023;14(1):7021.","DOI":"10.1038\/s41467-023-42883-2"},{"key":"15527_CR18","doi-asserted-by":"crossref","unstructured":"Winter J, Kunze R, Veit N, Kuerpig S, Meisenheimer M, Kraus D, et al. Targeting of glucose transport and the NAD pathway in neuroendocrine tumor (NET) cells reveals new treatment options. Cancers (Basel). 2023;15(5):1415.","DOI":"10.3390\/cancers15051415"},{"key":"15527_CR19","doi-asserted-by":"crossref","unstructured":"Suzuki K, Miura Y, Mochida Y, Miyazaki T, Toh K, Anraku Y, et al. Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors. J Control Release. 2019;301:28\u201341.","DOI":"10.1016\/j.jconrel.2019.02.021"},{"issue":"5","key":"15527_CR20","doi-asserted-by":"publisher","first-page":"712","DOI":"10.2174\/1574888X17666220827113434","volume":"18","author":"X Cao","year":"2023","unstructured":"Cao X, Cao Y, Zhao H, Wang P, Zhu Z. Prolyl 4-hydroxylase P4HA1 mediates the interplay between glucose metabolism and stemness in pancreatic cancer cells. Curr Stem Cell Res Ther. 2023;18(5):712\u20139.","journal-title":"Curr Stem Cell Res Ther"},{"key":"15527_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.leukres.2015.12.008","volume":"41","author":"T Matsumoto","year":"2016","unstructured":"Matsumoto T, Jimi S, Migita K, Takamatsu Y, Hara S. Inhibition of glucose transporter 1 induces apoptosis and sensitizes multiple myeloma cells to conventional chemotherapeutic agents. Leuk Res. 2016;41:103\u201310.","journal-title":"Leuk Res"},{"key":"15527_CR22","doi-asserted-by":"crossref","unstructured":"Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011;3(94):94ra70.","DOI":"10.1126\/scitranslmed.3002394"},{"issue":"5","key":"15527_CR23","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00280-016-3007-9","volume":"77","author":"F Zhao","year":"2016","unstructured":"Zhao F, Ming J, Zhou Y, Fan L. Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation. Cancer Chemother Pharmacol. 2016;77(5):963\u201372.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"15527_CR24","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/CAD.0000000000000529","volume":"28","author":"Q Chen","year":"2017","unstructured":"Chen Q, Meng YQ, Xu XF, Gu J. Blockade of GLUT1 by WZB117 resensitizes breast cancer cells to adriamycin. Anticancer Drugs. 2017;28(8):880\u20137.","journal-title":"Anticancer Drugs"},{"key":"15527_CR25","doi-asserted-by":"crossref","unstructured":"Shima T, Taniguchi K, Tokumaru Y, Inomata Y, Arima J, Lee SW, et al. Glucose transporter\u20131 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells. Oncol Rep. 2022;47(1):7.","DOI":"10.3892\/or.2021.8218"},{"key":"15527_CR26","doi-asserted-by":"publisher","first-page":"976117","DOI":"10.3389\/fphar.2022.976117","volume":"13","author":"RS Zhang","year":"2022","unstructured":"Zhang RS, Li ZK, Liu J, Deng YT, Jiang Y. WZB117 enhanced the anti-tumor effect of apatinib against melanoma via blocking STAT3\/PKM2 axis. Front Pharmacol. 2022;13:976117.","journal-title":"Front Pharmacol"},{"key":"15527_CR27","doi-asserted-by":"publisher","first-page":"11859","DOI":"10.2147\/IJN.S534976","volume":"20","author":"Z Ren","year":"2025","unstructured":"Ren Z, Zhao J, Li S, Yuan H. Targeting glucose transporter 1 (GLUT1) in cancer: molecular mechanisms and nanomedicine applications. Int J Nanomed. 2025;20:11859\u201379.","journal-title":"Int J Nanomed"},{"issue":"6","key":"15527_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.prp.2017.04.023","volume":"213","author":"LJ van Vugt","year":"2017","unstructured":"van Vugt LJ, van der Vleuten CJM, Flucke U, Blokx WAM. The utility of GLUT1 as a diagnostic marker in cutaneous vascular anomalies: A review of literature and recommendations for daily practice. Pathol Res Pract. 2017;213(6):591\u20137.","journal-title":"Pathol Res Pract"},{"issue":"48","key":"15527_CR29","doi-asserted-by":"publisher","first-page":"e12961","DOI":"10.1097\/MD.0000000000012961","volume":"97","author":"Y Deng","year":"2018","unstructured":"Deng Y, Zou J, Deng T, Liu J. Clinicopathological and prognostic significance of GLUT1 in breast cancer: A meta-analysis. Med (Baltim). 2018;97(48):e12961.","journal-title":"Med (Baltim)"},{"key":"15527_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.gene.2018.12.006","volume":"689","author":"B Zhang","year":"2019","unstructured":"Zhang B, Xie Z, Li B. The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: A meta-analysis. Gene. 2019;689:76\u201383.","journal-title":"Gene"},{"issue":"8","key":"15527_CR31","doi-asserted-by":"publisher","first-page":"13206","DOI":"10.18632\/oncotarget.14570","volume":"8","author":"X Chen","year":"2017","unstructured":"Chen X, Lu P, Zhou S, Zhang L, Zhao JH, Tang JH. Predictive value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis. Oncotarget. 2017;8(8):13206\u201313.","journal-title":"Oncotarget"},{"issue":"45","key":"15527_CR32","doi-asserted-by":"publisher","first-page":"e5324","DOI":"10.1097\/MD.0000000000005324","volume":"95","author":"CX Li","year":"2016","unstructured":"Li CX, Sun JL, Gong ZC, Lin ZQ, Liu H. Prognostic value of GLUT-1 expression in oral squamous cell carcinoma: A prisma-compliant meta-analysis. Med (Baltim). 2016;95(45):e5324.","journal-title":"Med (Baltim)"},{"key":"15527_CR33","doi-asserted-by":"crossref","unstructured":"Kim K, Park WY, Kim JY, Sol MY, Shin DH, Park DY, et al. Prognostic relevance of the expression of CA IX, GLUT-1, and VEGF in ovarian epithelial cancers. Korean J Pathol. 2012;46(6):532\u201340.","DOI":"10.4132\/KoreanJPathol.2012.46.6.532"},{"key":"15527_CR34","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.2147\/IJGM.S354108","volume":"15","author":"AT Ibrahiem","year":"2022","unstructured":"Ibrahiem AT, Fawzy MS, Abdulhakim JA, Toraih EA. GLUT1 and ASCT2 protein expression in papillary thyroid carcinoma patients and relation to hepatitis C virus: A Propensity-Score matched analysis. Int J Gen Med. 2022;15:2929\u201344.","journal-title":"Int J Gen Med"},{"key":"15527_CR35","doi-asserted-by":"crossref","unstructured":"Yang JW, Yuan LL, Gao Y, Liu XS, Wang YJ, Zhou LM, et al. (18)F-FDG PET\/CT metabolic parameters correlate with EIF2S2 expression status in colorectal cancer. J Cancer. 2021;12(19):5838\u201347.","DOI":"10.7150\/jca.57926"},{"issue":"6","key":"15527_CR36","first-page":"EC09","volume":"11","author":"I Seleit","year":"2017","unstructured":"Seleit I, Bakry OA, Al-Sharaky DR, Ragab RAA, Al-Shiemy SA. Evaluation of hypoxia inducible Factor-1alpha and glucose Transporter-1 expression in Non melanoma skin cancer: an immunohistochemical study. J Clin Diagn Res. 2017;11(6):EC09\u201316.","journal-title":"J Clin Diagn Res"},{"key":"15527_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-60761-806-5_3","volume":"664","author":"G Sauter","year":"2010","unstructured":"Sauter G. Representativity of TMA studies. Methods Mol Biol. 2010;664:27\u201335.","journal-title":"Methods Mol Biol"},{"key":"15527_CR38","doi-asserted-by":"crossref","unstructured":"Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159(6):2249\u201356.","DOI":"10.1016\/S0002-9440(10)63075-1"},{"key":"15527_CR39","doi-asserted-by":"crossref","unstructured":"Uhlen M, Bandrowski A, Carr S, Edwards A, Ellenberg J, Lundberg E, et al. A proposal for validation of antibodies. Nat Methods. 2016;13(10):823\u20137.","DOI":"10.1038\/nmeth.3995"},{"issue":"6","key":"15527_CR40","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"GT Consortium","year":"2013","unstructured":"Consortium GT. The Genotype-Tissue expression (GTEx) project. Nat Genet. 2013;45(6):580\u20135.","journal-title":"Nat Genet"},{"key":"15527_CR41","doi-asserted-by":"crossref","unstructured":"Lizio M, Abugessaisa I, Noguchi S, Kondo A, Hasegawa A, Hon CC, et al. Update of the FANTOM web resource: expansion to provide additional transcriptome atlases. Nucleic Acids Res. 2019;47(D1):D752\u20138.","DOI":"10.1093\/nar\/gky1099"},{"key":"15527_CR42","doi-asserted-by":"crossref","unstructured":"Lizio M, Harshbarger J, Shimoji H, Severin J, Kasukawa T, Sahin S, et al. Gateways to the FANTOM5 promoter level mammalian expression atlas. Genome Biol. 2015;16(1):22.","DOI":"10.1186\/s13059-014-0560-6"},{"key":"15527_CR43","doi-asserted-by":"crossref","unstructured":"Thul PJ, Akesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, et al. A subcellular map of the human proteome. Science. 2017;356(6340):eaal3321.","DOI":"10.1126\/science.aal3321"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15527-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15527-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15527-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:34:30Z","timestamp":1781627670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15527-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15527"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15527-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local ethics committee (Ethics Commission Hamburg, WF-049\/09) has approved the manufacturing and analysis of TMAs from archived remnants of diagnostic tissues. Patientsdata analysis without informed patient consent is covered by local laws (HmbKHG, \u00a7\u00a012).The use of archived remnants of diagnostic tissues for manufacturing of TMAs and their analysis for research purposes as well as patient data analysis has been approved by local laws (HmbKHG, \u00a7\u00a012) and by the local ethics committee (Ethics Commission Hamburg, WF-049\/09). All work has been carried out in compliance with the Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The rabbit recombinant GLUT1 antibody, clone MSVA-401R was provided from MS Validated Antibodies GmbH, Hamburg, Germany (owned by a family member of GS).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}